Clinical Trials Browser

Ovarian Neoplasms × tazemetostat × 90 days × Clear all

NCT03348631 2026-05-29

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

Phase 2 Active not recruiting

62 enrolled 14 charts

Ovarian Neoplasms